An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics

作者：Johnson Jeremy R^*; Lossignol Dominique; Burnell Nugent Mary; Fallon Marie T

来源：Journal of Pain and Symptom Management, 2013, 46(2): 207-218.

DOI：10.1016/j.jpainsymman.2012.07.014

• Cancer
• cannabinoid
• delta-9-tetrahydrocannabinol
• pain
• THC/CBD oromucosal spray

Context. Chronic pain in patients with advanced cancer poses a serious clinical challenge. The D9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (U. S. Adopted Name, nabiximols; Sativex (R)) is a novel cannabinoid formulation currently undergoing investigation as an adjuvant therapy for this treatment group.
Objectives. This follow-up study investigated the long-term safety and tolerability of THC/CBD spray and THC spray in relieving pain in patients with advanced cancer.
Methods. In total, 43 patients with cancer-related pain experiencing inadequate analgesia despite chronic opioid dosing, who had participated in a previous three-arm (THC/CBD spray, THC spray, or placebo), two-week parent randomized controlled trial, entered this open-label, multicenter, follow-up study. Patients self-titrated THC/CBD spray (n = 39) or THC spray (n = 4) to symptom relief or maximum dose and were regularly reviewed for safety, tolerability, and evidence of clinical benefit.
Results. The efficacy end point of change from baseline in mean Brief Pain Inventory-Short Form scores for "pain severity" and "worst pain" domains showed a decrease (i.e., improvement) at each visit in the THC/CBD spray patients. Similarly, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 scores showed a decrease (i.e., improvement) from baseline in the domains of insomnia, pain, and fatigue. No new safety concerns associated with the extended use of THC/CBD spray arose from this study.
Conclusion. This study showed that the long-term use of THC/CBD spray was generally well tolerated, with no evidence of a loss of effect for the relief of cancer-related pain with long-term use. Furthermore, patients who kept using the study medication did not seek to increase their dose of this or other pain-relieving medication over time, suggesting that the adjuvant use of cannabinoids in cancer-related pain could provide useful benefit. J Pain Symptom Manage 2013;46:207-218.

• 出版日期2013-8